Fesoterodine place among antimuscarinic drugs
On November 8–10, 2018, the 18th Congress of the Russian Urology Association and the Russian-Chinese Forum on Urology were held in Yekaterinburg, during which John Heesakkers, Head of the Section of Functional Urology and Neurosurgery of the Department of Urology of the Radboud Universiteit Nijmegen (Netherlands), gave a report “Fesoterodine in the treatment of overactive bladder. Comparison with other antimuscarinic drugs” on November 9, 2018.
References
1. Abrams P. The standartisation of terminology of lower urinary tract function // Neurourol. and Urodyn. 2002. Vol. 21. P.167–178.
2. Haylen B.T., de Ridder D., Freeman R.M. et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction // Neurourol. Urodyn. 2010. Vol. 29. P.4–20.
3. Drake M.J. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013 // Neurourology and Urodynamics, 2014. Vol. 33. P.622.
4. Irwin D.E., Kopp Z.S., Agatep B. et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction // BJU Int. 2011. Vol. 108(7). P.1132–1138.
5. Brown J.S., McGhan W.F., Chokroverty S. Comorbidities associated with overactive bladder // Am J. Manag. Care. 2000. Vol. 6(Suppl. 11). P.S574–S579.
6. Cardozo L., Khullar V., Wang J.T. et al. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? // BJU Int. 2010. Vol. 106(6). P.816–821.
7. Chapple C., van Kerrebroeck P., Tubaro A. et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder // Eur Urol. 2007. Vol. 52. P. 1204–1212.
8. Chapple C., Schneider T., Haab F. et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial // BJU Int. 2014. Vol. 114. P.418–426.
9. Kaplan S.A., Schneider T., Foote J.E. et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial // BJU Int. 2011. Vol. 107. P.1432–1440.
10. DuBeau C.E., Kraus S.R., Griebling T.L. et al. Effectof fesoterodine in vulnerable elderly subjects with urgency incontinence: a doube-blind, placebo controlled trial // J. Urol. 2014. Vol. 191. P.395–404.
11. Kerdraon J., Robain G., Jeandel C. et al. Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly // Progrès en urologie. 2014. Vol. 24. P.672–681.
12. Kay G.G., Maruff P., Scholfield D. et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine // Postgrad Med. 2012. Vol. 124(3). P.7–15.
13. Инструкция к препарату Товиаз РУ № ЛП-002016.
14. Chapple C., Matthias O., Kaplan S.A., Scholfield D. et al. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review // Current Medical Research and Opinion. 2015. Vol. 31(6). P.1201–1243.
15. Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged // J. Am Geriatr. Soc. 2009. Vol. 57. P.560–561.
16. Oelke M., Becher K., Castro-Diaz D. et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014) // Age Aging. 2015. Vol. 44(5). P.745–755.
2. Haylen B.T., de Ridder D., Freeman R.M. et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction // Neurourol. Urodyn. 2010. Vol. 29. P.4–20.
3. Drake M.J. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013 // Neurourology and Urodynamics, 2014. Vol. 33. P.622.
4. Irwin D.E., Kopp Z.S., Agatep B. et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction // BJU Int. 2011. Vol. 108(7). P.1132–1138.
5. Brown J.S., McGhan W.F., Chokroverty S. Comorbidities associated with overactive bladder // Am J. Manag. Care. 2000. Vol. 6(Suppl. 11). P.S574–S579.
6. Cardozo L., Khullar V., Wang J.T. et al. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? // BJU Int. 2010. Vol. 106(6). P.816–821.
7. Chapple C., van Kerrebroeck P., Tubaro A. et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder // Eur Urol. 2007. Vol. 52. P. 1204–1212.
8. Chapple C., Schneider T., Haab F. et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial // BJU Int. 2014. Vol. 114. P.418–426.
9. Kaplan S.A., Schneider T., Foote J.E. et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial // BJU Int. 2011. Vol. 107. P.1432–1440.
10. DuBeau C.E., Kraus S.R., Griebling T.L. et al. Effectof fesoterodine in vulnerable elderly subjects with urgency incontinence: a doube-blind, placebo controlled trial // J. Urol. 2014. Vol. 191. P.395–404.
11. Kerdraon J., Robain G., Jeandel C. et al. Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly // Progrès en urologie. 2014. Vol. 24. P.672–681.
12. Kay G.G., Maruff P., Scholfield D. et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine // Postgrad Med. 2012. Vol. 124(3). P.7–15.
13. Инструкция к препарату Товиаз РУ № ЛП-002016.
14. Chapple C., Matthias O., Kaplan S.A., Scholfield D. et al. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review // Current Medical Research and Opinion. 2015. Vol. 31(6). P.1201–1243.
15. Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged // J. Am Geriatr. Soc. 2009. Vol. 57. P.560–561.
16. Oelke M., Becher K., Castro-Diaz D. et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014) // Age Aging. 2015. Vol. 44(5). P.745–755.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
